Cynata Therapeutics Ltd. (OTCMKTS:CYYNF) Sees Large Growth in Short Interest

Cynata Therapeutics Ltd. (OTCMKTS:CYYNF) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 4,327 shares, a growth of ∞ from the April 15th total of 0 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 4,273 shares, the short-interest ratio is currently 1.0 days.

Cynata Therapeutics Stock Performance

CYYNF opened at $0.22 on Friday. The stock’s fifty day moving average is $0.22 and its two-hundred day moving average is $0.18. Cynata Therapeutics has a 52 week low of $0.15 and a 52 week high of $0.22.

Cynata Therapeutics Company Profile

Cynata Therapeutics is a clinical‐stage biotechnology company specializing in the development of cell therapies using its proprietary Cymerus™ platform. The Cymerus process leverages induced pluripotent stem cells (iPSCs) to generate mesenchymal stem cells (MSCs) on a large scale, aiming to overcome the variability and supply challenges associated with donor‐derived MSCs. By utilizing a single, well‐characterized iPSC master cell bank, the company seeks to deliver consistent, off‐the‐shelf cell therapies for a range of inflammatory and degenerative conditions.

The company’s lead product candidate, CYP-001, is an iPSC‐derived MSC therapy being evaluated in a Phase 1 clinical trial for the prevention and treatment of acute graft‐versus‐host disease in patients undergoing hematopoietic stem cell transplantation.